BioCentury
ARTICLE | Company News

Exelixis, Bristol-Myers deal

December 8, 2008 8:00 AM UTC

Bristol-Myers exercised its option to develop and commercialize XL413, triggering a $20 million milestone payment to Exelixis. In October, Exelixis submitted a data report to the pharma for the selec...